文献速递胸部肿瘤

替米木单抗用于复发性恶性间皮瘤二线或三线治疗(DETERMINE):一项多中心、国际、随机、双盲、安慰剂对照2b期试验

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
PubMed 文献 · Lancet Oncol · 2017-07-17

DETERMINE研究在19国105中心纳入571例经治晚期恶性间皮瘤患者,随机2:1接受替米木单抗(n=382)或安慰剂(n=189)。意向治疗人群中位总生存期替米木单抗组7.7个月(95%CI 6.8-8.9)vs 安慰剂组7.3个月(5.9-8.7),HR 0.92(95%CI 0.76-1.12),p=0.41,未显著延长。3级及以上治疗中出现不良事件替米木单抗组246/380(65%)vs 安慰剂组91/189(48%)。

要点

  • 替米木单抗较安慰剂未显著延长经治恶性间皮瘤患者总生存期(HR 0.92,p=0.41)。
  • 3级及以上不良事件替米木单抗组65% vs 安慰剂组48%,腹泻和结肠炎更常见。
  • 替米木单抗安全性特征与已知CTLA-4抑制剂一致。

核心结论

  • 在有既往治疗的恶性间皮瘤患者中,替米木单抗较安慰剂未显著延长总生存期。
  • 替米木单抗的安全性特征与已知的CTLA-4抑制剂安全性特征一致。
  • 关于免疫联合方案能否在恶性间皮瘤中提供优于单药的疗效,相关研究正在进行中。

研究设计与样本

  • DETERMINE为双盲、安慰剂对照2b期试验,在19个国家105个研究中心开展。
  • 纳入不可切除的胸膜或腹膜恶性间皮瘤、既往接受过一线或二线系统治疗后进展、年龄≥18岁、ECOG体能状态0或1、具有可测量病灶的患者。
  • 患者按2:1随机分组,按EORTC风险状态(低危vs高危)、治疗线数(二线vs三线)和解剖部位(胸膜vs腹膜)分层。
  • 替米木单抗10 mg/kg或安慰剂静脉给药,每4周一次共7剂,此后每12周一次,直至达到治疗终止标准。
  • 主要终点为意向治疗人群的总生存期;安全性在所有至少接受一剂研究药物的患者中评估。

主要发现

  • 2013年5月17日至2014年12月4日,571例患者随机接受替米木单抗(n=382)或安慰剂(n=189);569例接受了治疗,替米木单抗组2例因未接受治疗被排除在安全性人群之外。
  • 截至2016年1月24日数据截止日,替米木单抗组382例中307例(80%)死亡,安慰剂组189例中154例(81%)死亡。
  • 意向治疗人群中位总生存期替米木单抗组7.7个月(95%CI 6.8-8.9)vs 安慰剂组7.3个月(95%CI 5.9-8.7),HR 0.92(95%CI 0.76-1.12),p=0.41。
  • 3级及以上治疗中出现不良事件替米木单抗组246/380(65%)vs 安慰剂组91/189(48%);最常见为呼吸困难34例(9%)vs 27例(14%)、腹泻58例(15%)vs 1例(<1%)、结肠炎26例(7%)vs 无。
  • 导致死亡的治療中出现事件替米木单抗组36/380(9%)vs 安慰剂组12/189(6%);治疗相关不良事件导致死亡替米木单抗组5例(1%)vs 安慰剂组无。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma. METHODS: DETERMINE was a double-blind, placebo-controlled, phase 2b trial done at 105 study centres across 19 countries in patients with unresectable pleural or peritoneal malignant mesothelioma who had progressed after one or two previous systemic treatments for advanced disease. Eligible patients were aged 18 years or older with Eastern Cooperative Oncology Group performance status of 0 or 1 and measurable disease as defined in the modified Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0 for pleural mesothelioma or RECIST version 1.1 for peritoneal mesothelioma. Patients were randomly assigned (2:1) in blocks of three, stratified by European Organisation for Research and Treatment of Cancer status (low risk vs high risk), line of therapy (second line vs third line), and anatomic site (pleural vs peritoneal), by use of an interactive voice or web system, to receive intravenous tremelimumab (10 mg/kg) or placebo every 4 weeks for 7 doses and every 12 weeks thereafter until a treatment discontinuation criterion was met. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug. The trial is ongoing but no longer recruiting participants, and is registered with ClinicalTrials.gov, number NCT01843374. FINDINGS: Between May 17, 2013, and Dec 4, 2014, 571 patients were randomly assigned to receive tremelimumab (n=382) or placebo (n=189), of whom 569 patients received treatment (two patients in the tremelimumab group were excluded from the safety population because they did not receive treatment). At the data cutoff date (Jan 24, 2016), 307 (80%) of 382 patients had died in the tremelimumab group and 154 (81%) of 189 patients had died in the placebo group. Median overall survival in the intention-to-treat population did not differ between the treatment groups: 7·7 months (95% CI 6·8-8·9) in the tremelimumab group and 7·3 months (5·9-8·7) in the placebo group (hazard ratio 0·92 [95% CI 0·76-1·12], p=0·41). Treatment-emergent adverse events of grade 3 or worse occurred in 246 (65%) of 380 patients in the tremelimumab group and 91 (48%) of 189 patients in the placebo group; the most common were dyspnoea (34 [9%] patients in the tremelimumab group vs 27 [14%] patients in the placebo group), diarrhoea (58 [15%] vs one [<1%]), and colitis (26 [7%] vs none). The most common serious adverse events were diarrhoea (69 [18%] patients in the tremelimumab group vs one [<1%] patient in the placebo group), dyspnoea (29 [8%] vs 24 [13%]), and colitis (24 [6%] vs none). Treatment-emergent events leading to death occurred in 36 (9%) of 380 patients in the tremelimumab group and 12 (6%) of 189 in the placebo group; those leading to the death of more than one patient were mesothelioma (three [1%] patients in the tremelimumab group vs two [1%] in the placebo group), dyspnoea (three [1%] vs two [1%]); respiratory failure (one [<1%] vs three [2%]), myocardial infarction (three [1%] vs none), lung infection (three [1%] patients vs none), cardiac failure (one [<1%] vs one [<1%]), and colitis (two [<1%] vs none). Treatment-related adverse events leading to death occurred in five (1%) patients in the tremelimumab group and none in the placebo group. The causes of death were lung infection in one patient, intestinal perforation and small intestinal obstruction in one patient; colitis in two patients, and neuritis and skin ulcer in one patient. INTERPRETATION: Tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malignant mesothelioma. The safety profile of tremelimumab was consistent with the known safety profile of CTLA-4 inhibitors. Investigations into whether immunotherapy combination regimens can provide greater efficacy than monotherapies in malignant mesothelioma are ongoing. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017. PMID: 28729154. doi:10.1016/S1470-2045(17)30446-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。